C
Corvus Pharmaceuticals D
D
CRVS
2.99500
USD
-0.21
(-6.55%)
مغلق
حجم التداول
16,861
الربح لكل سهم
-0
العائد الربحي
-
P/E
-3
حجم السوق
204,066,709
الأخبار المقالات
العنوان: Corvus Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).